SANOFICONRBSESANOFI CONS HEALTHC IND LHighNeutral
Announced Wed, 28 Oct, 2026 · 18:52 IST

Q3 revenue rises 12%, profit after tax up 22% year on year

Ebitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing

SANOFICONR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

The board approved unaudited Q3 FY26 results. Revenue rose 12% to ₹2,631 million, profit before tax rose 22% to ₹1,027 million, and EPS rose 22% to ₹33.26. Nine-month revenue rose 16% to ₹7,280 million and profit after tax rose 23% to ₹2,132 million. The auditor issued an unmodified limited review. Prior-year results included a ₹66 million exceptional reversal, while product relaunches affect comparisons.

Likely market impact

Strong revenue, profit and margin growth is positive for shareholders, though product relaunches mean comparisons are not fully like for like.